As AI transforms drug development, biotechs might not need as much Big Pharma support

AI is making its mark on the pharma market, presenting opportunities for Big Pharma to cut down on drug development costs and fast-track new discoveries. But AI’s capabilities also open the door for smaller biotechs to remain independent rather than leaning on deep-pocketed, established pharmas, according to a report from S&P Global Ratings.